Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

Starting soon · Phase 3

Conditions studied: Retinal Disease

In brief

This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.

Key facts

Study ID

NCT05750589

Run by

iRenix Medical, Inc.

People needed

240

Starts

2026-09-01

Expected to finish

2027-12-31

Last updated by the study team

2026-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Capable of giving informed consent
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, ≥ 18 years of age and receiving intravitreal anti-VEGF injections in one or both eyes

You may not qualify if…

• Current or past diagnosis of endophthalmitis
• Current diagnosis of uveitis
• Monocular patients (vision 20/100 or worse in one eye) who are receiving injections in the better seeing eye
• Current use of viscous lidocaine products for ocular anesthesia prior to IVT
• Currently receiving intravitreal steroid injections
• Concurrent participation in another clinical trial
• Females who are pregnant, planning to become pregnant or lactating

Where it is running

• R. Gary Lane, II MD — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.